December 2022 Update on Bioxytran, Inc. (BIXT-OTCBB)

Posted by Karen Goldfarb

December 21, 2022 at 2:30 PM

A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. 


Read More

Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic